Address: Beijing's xizhimen south street, xicheng district
The British garden 1 floor. Room 824
Zip code: 100035
Telephone: 010-58562339
Fax: 010-58562339
Email address: cngjzj@163.com
Web site (click on the url link directly left) :
http://www.cngjzj.com/
Blog (click on the url link directly left) :
http://blog.sina.com.Cn/CNGJZJ
To xizhimen south street, xicheng district building to the British garden route
L airport line 1
Take the airport shuttle from the airport, the dongzhimen station transfer to metro line 2 to xizhimen direction and get off at xizhimen station, from C outbound, go straight to the east 100 meters on the right side to xizhimen south street, north to walk to the t-junction namely to the British garden 1 floor downstairs.
L airport line 2
From the capital airport take airport bus to xidan, get off at no.22, take a taxi to xizhimen south street English garden 1 floor.
L bus subway near:
106 bus GuanYuan: 107 road, express way
Bus: xizhimen south road 387, 44 road, inner ring 800, 816 road, inner ring 820, 845 road
Che zhuang: subway line two
Xizhimen subway: metro line 2
Buses and attempts: 107 road, 118 road, 701 road
Buses and north zhuang: 209 road, 375 road, 392 road
Your position is：
Home >>
R&Dplatform >>
R&Dplatform
2015年11月05日
复制链接
打印
大 中 小
Group method to raise 1.46 billion to increase product research and development and production
Source: HeXun author: gu
The 2015-11-03 09:26:25
Events: the company intends to non-public offering is not more than $1.46 billion for "oprah azole series of innovative products depth development and industrialization of upgrade", "therapeutic antibody drug research and development and industrialization projects", "long-lasting microsphere technology r&d platform construction project" and added liquidity and repay bank loans.
Shekinah analysis:
1, the company has been in the anti-tumor Chinese medicine auxiliary medication, assisted reproduction, digestive drugs, and other characteristics of specialized care field market advantage, at the same time continue to strengthen with monoclonal antibody drugs as the core of biological medicine field, and actively layout with gene diagnosis related business as the core of precision medical field.
2, ai oprah azole series of innovative products depth development and industrialization of upgrade in existing products "oprah azole enteric-coated metformin hydrochloride" lian (1) the depth development, on the basis of the product is used in the treatment of duodenal ulcer. 12-14 years, the company to the production of thiazole enteric-coated metformin hydrochloride is about 3 million, 5.2 million and 5.2 million respectively, fast growth; Project implementation will be ai oprah azole new applicable disease and new products and improve production capacity.
3, a therapeutic antibody drug research and development and industrialization projects will produce single resistance in the field of autoimmune diseases and cancer drugs, used in the treatment of rheumatoid arthritis and breast cancer. Is expected to average annual net profit of 340 million yuan, embedded yields (after tax) is 40.89%, good prospects.
4, long-acting microsphere technology r&d platform construction project will build long-term microspheres controlled-release formulation technology platform, the implementation of research and development of new varieties and pilot, production workshop construction.
5, the implementation of the project will help the company expand the scale of existing products, improve product market share; Is beneficial to the optimization of products structure, and further improve the level of product quality and process technology, comprehensive research and development ability and independent innovation ability of ascension.
